PharmaFocus Today – Page 77 – media

Study reveals cardiovascular health could be biggest risk factor for dementia

Dementias, including Alzheimer’s disease, are estimated to affect 944,000 people in the UK Researchers from University College London (UCL) have revealed that cardiovascular health could be the biggest risk factor associated with future dementia. Published in the Lancet Public Health, the study was funded by the National Institute for Health and Care Research’s Three Schools’ Dementia Research Programme. Estimated to affect 944,000 people in the UK, dementia is a general term for the impaired ability to remember, think, or make decisions that affects everyday life. The most prevalent dementias include Alzheimer’s disease, vascular dementia, Lewy body dementia and frontotemporal dementia. Researchers analysed and extracted data from 27 papers involving people with dementia worldwide, with data collected between 1947 and 2015 and the latest paper published in 2020. The extracted information from each paper about dementia risk factors was then used to calculate what proportion of dementia cases were attributable to ...
- Source: drugdu
- 102
- July 5, 2024
Study finds headache drug could prevent overuse of acute migraine medications

Chronic migraine is a neurological condition estimated to affect up to 2.2% of people globally A study led by researchers at King’s College London (KCL) and funded by AbbVie has revealed that a headache drug helps to prevent the overuse of acute migraine medication. Published in Neurology, AbbVie’s Qulipta (atogepant) was shown to be effective in decreasing migraine days in adults living with chronic migraine. Estimated to affect up to 2.2% of the global population, chronic migraine is a debilitating neurological disease where people regularly experience at least 15 days a month of headaches. Most often, headaches can be intensified by the overuse of acute migraine medications such as triptans, ergots and simple analgesics, leading to worse pain relief outcomes over a 24-hour period. Funded by AbbVie, the study assessed the efficacy of Qulipta in preventing chronic migraine in patients who met the criteria for acute medicine overuse as well ...
- Source: drugdu
- 67
- July 5, 2024
Beacon secures $170m to advance ophthalmic gene therapies

Beacon Therapeutics has raised $170m in a Series B funding round to accelerate the development of its lead asset AGTC-501, for X-linked retinitis pigmentosa (XLRP). The financing round was led by life sciences venture capital firm Forbion, alongside existing investors Syncona Limited, Oxford Science Enterprises and the University of Oxford, and also featured initial investments from TCGX and Advent Life Sciences. The British investment trust Syncona previously acquired Applied Genetic Technologies Corporation (AGTC) for $23.5m in October 2023. AGTC inherited a portfolio of ophthalmic pipeline candidates, including AFTC-501, an adeno-associated virus (AAV) gene therapy. XLRP is a genetic disorder that causes progressive vision loss, primarily in males, due to retinal degeneration. AFTC-501, now transferred to Beacon, has been investigated in several clinical trials for XLRP. Promising interim data from the Phase II SKYLINE trial (NCT03316560) was announced in February 2024, showing that 63% of eyes treated with high-dose AGTC-501 experienced ...
- Source: drugdu
- 99
- July 5, 2024
Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence

As Eli Lilly’s Kisunla (donanemab) enters the Alzheimer’s treatment space, its leading competitor Biogen is undergoing therapy diversification after completing its $1.15bn acquisition of Human Immunology Biosciences (HI-Bio). The deal, which was agreed upon in May this year and includes $650m in milestone payments, sees Biogen bolster its pipeline with US-based HI-Bio’s anti-CD38 monoclonal antibody candidate felzartamab. Biogen’s head of development Priya Singhal said the company is “very excited” about the addition of felzartamab to its rosters in a 2 July press release, adding that Biogen will advance the candidate to Phase III now the transaction is complete. Felzartamab has already demonstrated positive Phase II data in a range of immune-mediated diseases, including IgA nephropathy (IgAN), antibody-mediated rejection (AMR), and primary membranous nephropathy (PMN). The Phase III development plans are for all three diseases, according to Biogen. Felzartamab was originally developed by MorphoSys as a possible competitor to Johnson & ...
- Source: drugdu
- 86
- July 5, 2024
Advanced Blood Test Helps Improve Cancer Treatments

Early detection of cancer significantly increases the likelihood of successful treatment across various cancer types. In addition to personalized evaluation of therapy benefits and risks, continuous monitoring of treatment success is vital. Traditionally, oncologists rely on imaging technology and invasive procedures such as tissue biopsies, punctures, and endoscopic measures to monitor patients. Now, researchers have further developed an advanced method, a type of liquid biopsy that utilizes blood samples rather than direct tissue sampling for detecting various types of cancer. The technique, developed by researchers at the University of Zurich (UZH, Zurich, Switzerland) and the University Hospital Zurich (USZ, Zurich, Switzerland), involves sequencing and analyzing DNA fragments that circulate in the blood of patients to identify changes specific to particular cancers. The research team examined alterations in the number and length distribution of the DNA fragments, enabling them to distinguish between biologically less and more aggressive metastatic cancers even earlier ...
- Source: drugdu
- 95
- July 4, 2024
Novel AI-Based Analysis Method Uncovers New Insight into ALS Progression

Amyotrophic Lateral Sclerosis (ALS) is a fatal condition where motor neurons, which are crucial for controlling movement, progressively die. Currently, there is no cure for ALS, and patients typically live between 2 and 5 years after diagnosis. Now, in a new study published in Science Advances, researchers have shown how to leverage artificial intelligence (AI) to gain deeper insights into ALS progression. The study, led by researchers from the School of Psychology and Neuroscience at the University of St Andrews (Scotland, UK), in collaboration with the Department of Neuroscience, University of Copenhagen (Copenhagen, Denmark), found that certain neural circuits that control movement are compromised early in the disease, while others deteriorate later as the disease progresses. The techniques used in the study allow for the simultaneous analysis of multiple cell types within the spinal cord, enhanced by an innovative AI-driven analytical method. This enabled the identification of specific networks of ...
- Source: drugdu
- 66
- July 4, 2024
FDA Approves Lilly’s Kisunla for the Treatment of Early Symptomatic Alzheimer’s Disease

By Don Tracy, Associate Editor Kisnula is the first amyloid plaque-targeting therapy that allows for stopping treatment upon plaque removal, company says. The FDA has approved Eli Lilly’s Kisunla (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion) to treat adults with early symptomatic Alzheimer’s disease, including mild cognitive impairment and mild dementia with confirmed amyloid pathology. According to the company, Kisunla the first amyloid plaque-targeting therapy that allows for stopping treatment upon plaque removal, potentially reducing costs and infusion frequency. Approval was based on results from the Phase III TRAILBLAZER-ALZ 2 study.1 “Kisunla demonstrated very meaningful results for people with early symptomatic Alzheimer’s disease, who urgently need effective treatment options. We know these medicines have the greatest potential benefit when people are treated earlier in their disease, and we are working hard in partnership with others to improve detection and diagnosis,” said Anne White, EVP, president, Lilly Neuroscience, Eli ...
- Source: drugdu
- 96
- July 4, 2024
Eli Lilly Alzheimer’s Drug Lands FDA Approval, Introducing Competition to Eisai’s Leqembi

Eli Lilly’s Kisunla is now FDA approved for treating patients in the early stages of Alzheimer’s disease. In addition to slowing cognitive decline and disease progression, clinical trial results showed that amyloid beta plaques were reduced to the point where some patients could stop taking the infused therapy. By Frank VinluanEli Lilly Alzheimer’s disease drug has received its long-awaited FDA approval, bringing patients a treatment that works similarly to an Eisai medication for the neurodegenerative disorder but with dosing advantages that patients might prefer. The Tuesday regulatory decision comes less than a month after an FDA advisory committee voted unanimously that the benefits of the Lilly drug in slowing cognitive decline outweigh its safety risks. The approval covers the treatment of Alzheimer’s patients with mild cognitive impairment or mild dementia, the same population that was evaluated in clinical trials. Known in development as donanemab, Lilly will market its new Alzheimer’s ...
- Source: drugdu
- 111
- July 4, 2024
Female cancer survivors at low risk of developing obstetric complications

According to WHO, around 15% of pregnant women will develop an obstetric complication Researchers from the Universities of Birmingham, Bristol and Edinburgh have revealed that the majority of women who have survived cancer are at low risk of developing obstetric complications. The study published in the Lancet Oncology was funded by Children with Cancer UK, the Brain Tumour Charity and the Academy of Medical Sciences. Currently the most prevalent cancer in the UK, breast cancer affects around 55,000 women every year. According to the World Health Organization, around 15% of all pregnant women will develop a potentially life-threatening obstetric complication, including pyrexia and sepsis intrapartum haemorrhage, in pregnancy and childbirth and some will require a major obstetrical intervention to survive. After analysing data from almost 100,000 female survivors of cancer who had been diagnosed between the ages of 15 and 39 years between 1971 and 2006, approximately 21,437 births had ...
- Source: drugdu
- 100
- July 4, 2024
Researchers find whole genome sequencing improves care for paediatric cancer

Affecting around 3,755 young people in the UK every year, leukaemia is the most commonly diagnosed cancer in children Researchers from the Wellcome Sanger Institute, Cambridge University Hospitals NHS Trust, Great Ormond Street Hospital and the University of Cambridge have revealed that whole genome sequencing (WGS) can improve the clinical care of children with cancer. Published in Nature Medicine, the study showed that cutting-edge genomic testing could improve the management of care in real-time while providing more benefits compared to all other current tests combined. Every year, around 3,755 young people are diagnosed with cancer in the UK, with some of the most prevalent childhood cancers including lymphoma, muscle or bone cancers, neuroblastoma and leukaemia, which is the most commonly diagnosed cancer in children. WGS is a single test that provides a complete readout of the tumour’s entire genetic code while identifying every single cancer-causing mutation. Researchers, for the first ...
- Source: drugdu
- 94
- July 4, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.